RE:RE:RE:RE:“Second mouse gets the cheese “
January 18, 2024 - Oncolytics virus company CG Oncology is looking to raise $209 million from its upcoming IPO.
The company's OV is designed to infect and replicate in tumor cells, directly killing them while also causing the release of tumor-derived antigens and GM-CSF to stimulate an immune attack. CG has initially been developing the candidate as a treatment for non-muscle invasive bladder cancer. (non-metastatic) Its also called superficial bladder cancer.
The biotech has said it is looking to sell 11.8 million shares at a price of between $16 and $18 apiece.
https://www.fiercebiotech.com/biotech/cg-oncology-aims-209m-ipo-more-biotechs-eye-path-public-markets